Gain Therapeutics, Inc.

For the period ended Sep 30, 2026. Filed Nov 10, 2026.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Sep 30, 2026 · Filed Nov 10, 2026

GANX$1.08-0.9%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Consolidated Balance Sheets (Unaudited)

CONDENSED CONSOLIDATED BALANCE SHEETS


· · · September 30, · · December 31,
· · · 2026 · · 2025
Assets · · · ·
Current assets: · · · ·
Cash and cash equivalents	$11,697,570	$20,837,628
Tax credits	80,906	179,701
Prepaid expenses and other current assets	919,448	1,219,809
Total current assets	12,697,924	22,237,138

Noncurrent assets:
Property and equipment, net	40,324	74,916
Internal-use software, net	65,741	102,837
Operating lease right-of-use assets	367,562	334,090
Restricted cash	34,445	36,296
Long-term deposits and other noncurrent assets	25,891	33,698
Total noncurrent assets	533,963	581,837
Total assets	$13,231,887	$22,818,975

Liabilities and stockholders' equity
Current liabilities:
Accounts payable	$602,711	$825,027
Operating lease liabilities - current	152,796	119,876
Other current liabilities	1,493,754	2,306,624
Loans - current	119,656	100,869
Total current liabilities	2,368,917	3,352,396

Noncurrent liabilities:
Defined benefit pension plan	308,060	390,509
Operating lease liabilities - noncurrent	215,198	211,238
Loans - noncurrent	189,056	300,084
Total noncurrent liabilities	712,314	901,831
Total liabilities	$3,081,231	$4,254,227

Stockholders’ equity
Preferred stock, $0.0001 par value; 10,000,000 shares authorized; nil shares issued and outstanding as of September 30, 2026 and December 31, 2025, respectively	$—	$—
Common stock, $0.0001 par value: 100,000,000 shares authorized; 44,324,134 and 42,073,807 shares issued and outstanding as of September 30, 2026 and December 31, 2025, respectively	4,434	4,209
Additional paid-in capital	124,074,293	119,139,677
Accumulated other comprehensive income	872,647	776,869
Accumulated deficit	(114,800,718)	(101,356,007)
Total stockholders’ equity	10,150,656	18,564,748
Total liabilities and stockholders’ equity	$13,231,887	$22,818,975

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.